AstraZeneca shares fell sharply in European trading after the company and partner Ionis Pharmaceuticals announced that their Phase 3 clinical trial for Wainua failed to meet its primary endpoint in the treatment of transthyretin amyloidosis (ATTR).
The negative data represents a significant blow to the development pipeline for the experimental therapy, which had been viewed as a potential growth driver in the rare disease space.
The market reaction was immediate and severe, with AstraZeneca's stock price dropping on the news.
Investors are now reassessing the value proposition of the Wainua program, which aimed to address a subset of patients with ATTR who are not adequately managed by existing therapies.
The failure to hit the primary statistical target raises questions about the drug's efficacy and its ability to secure regulatory approval in key markets.
Ionis Pharmaceuticals, the partner in the development of Wainua, also faced downward pressure as the shared liability of the trial failure became clear.